Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures
Neurodegenerative Disease Management · 2024-02 · 14 (1) · 11-20
DOI: 10.2217/nmt-2023-0040 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Neurodegenerative Disease Management, online erschienen am 06.02.2024. Verfasst von Michael R Haupts und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Heinrich Heine University Düsseldorf, Düsseldorf, 40225, Germany. Hauptthemen laut MEDLINE: Cannabidiol, Multiple Sclerosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aim
This prospective, multicenter, open-label, noninterventional 12-week study investigated the effectiveness and tolerability of add-on nabiximols oromucosal spray (Sativex®) in the real-world setting in Germany. Patients & methods: The main analysis set comprised 51 adult patients (49 nabiximols responders) with multiple sclerosis (MS) spasticity.
Results
The mean overall goal attainment scale score (primary outcome measure) increased by 46% from baseline to week 12 (35.2 vs 51.4; p < 0.001). Mean gait speed was improved by 23% at 4 and 12 weeks. Clinically meaningful improvements in mean 0-10 numerical rating scale scores for spasticity, pain, sleep quality and urinary bladder dysfunction were recorded at 4 and 12 weeks.
Conclusion
Nabiximols is a useful therapeutic option for patients with MS spasticity. People with multiple sclerosis (MS) spasticity experience a variety of symptoms and have individual expectations about a new treatment. This study investigated patients' perceptions about the effectiveness and tolerability of nabiximols oromucosal spray (Sativex®) when added to current medications for spasticity. Common treatment goals for patients (n = 51) were less pain, better walking and improved sleep. After 12 weeks of treatment, 62% of selected treatment goals were achieved ‘as expected’ or ‘better than expected’ and 65% of patients considered their spasticity to be ‘much improved’. Meaningful improvements were recorded in spasticity-related symptoms of pain, sleep quality and bladder problems. Few side effects were reported. Nabiximols may be useful for MS patients with a poor response to usual spasticity medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Heinrich Heine University Düsseldorf, Düsseldorf, 40225, Germany.
- O. Meany Consultancy GmbH, Hamburg, 22339, Germany.
- Klinik für Neurologie, Juliusspital Würzburg Klinikum Würzburg Mitte gGmbH, Würzburg, 97070, Germany.
Zitieren
APA
Haupts, M. R., Essner, U., & Mäurer, M. (2024). Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures. Neurodegenerative Disease Management, 14(1), 11-20. https://doi.org/10.2217/nmt-2023-0040
Vancouver
Haupts MR, Essner U, Mäurer M. Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures. Neurodegenerative Disease Management. 2024;14(1):11-20. doi:10.2217/nmt-2023-0040
BibTeX
@article{Haupts2024,
author = {Haupts, Michael R and Essner, Ute and Mäurer, Mathias},
title = {Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures},
journal = {Neurodegenerative Disease Management},
year = {2024},
volume = {14},
number = {1},
pages = {11--20},
doi = {10.2217/nmt-2023-0040}
}
EUVIMED